Trial Assessing Atezolizumab in Triple-Negative Breast Cancer Misses End Point
Findings showed that the study did not meet statistical significance for progression free survival.
Diagnosis & Disease Information
FDA Approves First Antibody-Drug Conjugate for Metastatic Triple-Negative Breast Cancer
The FDA has granted accelerated approval to Trodelvy (sacituzumab govitecan-hziy; Immunomedics) for the treatment of adult patients with metastatic triple-negative breast cancer (mTNBC) who have received at least 2 prior therapies for metastatic disease.
Novel Protein Landscape Identified for Metaplastic Breast Cancer
Biomarker identification could allow for precision therapy in women with this subtype.
Effect of Clinical and Treatment Factors on Survival Outcomes of Triple Negative Breast Cancer Patients
[Breast Cancer: Targets and Therapy] A retrospective chart review of a cohort of patients with TNBC found that tumor size and nodal status is associated with DFS, and radiotherapy technique and fractionation protocol were not associated with differences in either DFS or OS.
Adding Pembrolizumab May Up Response in Triple-Negative Breast Cancer
Pathological complete response rate higher with pembrolizumab plus neoadjuvant chemotherapy.
Metabolic Syndrome May Affect Survival in Postmenopausal Women With Triple-Negative Breast Cancer
Researchers analyzed the association between baseline metabolic syndrome components and survival outcomes in women diagnosed with TNBC.
Chemoimmunotherapy Increases Survival in Triple-Negative Breast Cancer
Atezolizumab plus nab-paclitaxel prolongs progression-free survival in metastatic disease.
cfDNA Profiling Prognostic for Survival in Metastatic Triple-Negative Breast Cancer
Despite other clinicopathologic factors, patients with a tumor fraction of 10% or greater were more than twice as likely to pass away as those with a fraction of less than 10%.
Effect of Statins on Breast Cancer Recurrence and Mortality: A Review
[Breast Cancer: Targets and Therapy] Researchers present a review of study findings on the effect of statins on clinical outcomes for patients with breast cancer.
Examining the Role of Anti-PD-1 Immunotherapy in Advanced Triple-negative Breast Cancer
Breast cancer was previously thought to not be immunogenic in nature, but a subset of patients with breast cancer, primarily with triple negative disease, have exhibited robust levels of tumor infiltrating leukocytes.
- Loading...
Loading...
Next post in Breast Cancer
Loading... 
Loading...